Common sense tells me that if given a choice between inhaler and needle, I would pay twice as much for the former. Doctors prescribe whatever the patients want. If patients want Afrezza, surely they will prescribe. Insurance's refusal to cover risks the chance of losing customers. Market penetration is not a hotly debated issue.